MG
CRSP icon

Marex Group’s CRISPR Therapeutics CRSP Stock Holding History

Marex Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.3M Buy
170,584
+36,487
+27% +$1.92M 0.04% 186
2026
Q1 		$6.38M Buy
134,097
+6,551
+5% +$346K 0.04% 202
2025
Q4 		$6.69M Buy
127,546
+3,777
+3% +$226K 0.04% 192
2025
Q3 		$8.02M Buy
123,769
+104,286
+535% +$5.99M 0.06% 155
2025
Q2 		$948K Buy
19,483
+692
+4% +$26.8K 0.01% 295
2025
Q1 		$639K Sell
18,791
-5,174
-22% -$219K 0.01% 290
2024
Q4 		$943K Buy
23,965
+1,637
+7% +$77.3K 0.02% 251
2024
Q3 		$1.05M Buy
22,328
+1,742
+8% +$88.4K 0.02% 206
2024
Q2 		$1.11M Buy
20,586
+7,486
+57% +$433K 0.03% 213
2024
Q1 		$893K Buy
13,100
+33
+0.3% +$2.36K 0.03% 188
2023
Q4 		$818K Buy
13,067
+2,389
+22% +$132K 0.03% 241
2023
Q3 		$485K Sell
10,678
-840
-7% -$43.4K 0.07% 116
2023
Q2 		$647K Sell
11,518
-5,368
-32% -$305K 0.12% 115
2023
Q1 		$764K Buy
16,886
+7,036
+71% +$342K 0.1% 134
2022
Q4 		$400K Buy
+9,850
New +$523K 0.06% 190

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marex Group's CRSP Position: Q2 2026 in Review

Marex Group increased its CRISPR Therapeutics (CRSP) stake by 27% in Q2 2026, buying an estimated $1.92M and bringing the position to 170,584 shares worth $9.3M. The position accounts for 0.04% of the portfolio, ranked #186.

Marex Group first reported a position in CRSP in Q4 2022 and has held it in 15 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Marex Group held 170,584 shares of CRISPR Therapeutics worth $9.3M as of Q2 2026.
  • Marex Group bought 36,487 CRISPR Therapeutics shares in Q2 2026, an estimated $1.92M.
  • CRISPR Therapeutics made up 0.04% of Marex Group's portfolio in Q2 2026, its #186 holding.
  • Marex Group first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.